Unique ID issued by UMIN | UMIN000016959 |
---|---|
Receipt number | R000019602 |
Scientific Title | Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients Analysed by C13 Breath Test |
Date of disclosure of the study information | 2015/04/01 |
Last modified on | 2016/04/29 10:27:29 |
Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients Analysed by C13 Breath Test
Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients
Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients Analysed by C13 Breath Test
Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients
Japan |
T2DM
Endocrinology and Metabolism |
Others
NO
To explore the effect of lixisenatide on gastric emptying, a major determinant of postprandial glycemia, using C13-acetate breath test
Pharmacodynamics
Tlag (Tmax-cal) and T1/2 on C13-acetate breath test carried out after insulin/lixisenatide treatment
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Medicine |
Antidiabetic treatment carried out before admission is switched to insulin therapy on admission. The dose of insulin is titrated up to achieve a target fasting plasma glucose level of less than 140 mg/dl. Lixisenatide therapy is subsequently initiated at 10 microgram QD, and the dose is increased in increments of 5 microgram at 1- or 2-day intervals to a maximum level of 20 microgram QD.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
(1)Japanese T2DM patients
(2)Patients treated with OAD and/or injection therapy including insulin and GLP-1 receptor agonist except lixisenatide
(3)HbA1c >= 7.0% at screening visit
(4)Male and female patients aged 20-80 years
(1)Patients with history of chronic pancreatitis, inflammatory bowel disease, pancreatectomy or gastrectomy
(2)Patients with history of metabolic acidosis including diabetic ketoacidosis during the previous 1 year
(3)Patients with history of stroke or myocardial infarction requiring hospitalization during the previous 6 months
(4)Patients with severe or uncontrolled congestive heart failure
(5)Patients with drug or alcohol abuse during the previous 6 months
(6)Patients having hepatic dysfunction with AST or ALT greater than 5 times the upper limit of the normal laboratory range at the time of screening
(7)Patients having uncontrolled hypertension with a resting systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mmHg at the time of screening
(8)Patients with end-stage renal dysfunction and/or dialysis
(9)Patients having clinically relevant history of gastrointestinal disease with prolonged nausea and vomiting during the previous 6 months
(10)Pregnant or possibly pregnant women
(11)Patients judged as inadequate to participate in the present study by investingator or sub-investigator
20
1st name | |
Middle name | |
Last name | Makoto Ohashi |
Osaka Rosai Hospital
Center for Diabetes Mellitus
1179-3 Nagasone-cho, Sakai, Osaka 591-8025, Japan
072-252-3561
otokam@osakah.johas.go.jp
1st name | |
Middle name | |
Last name | Yoshimoto Kiyohara |
Osaka Rosai Hospital
Center for Diabetes Mellitus
1179-3 Nagasone-cho, Sakai, Osaka 591-8025, Japan
072-252-3561
y-kiyohara@osakah.johas.go.jp
Osaka Rosai Hospital
Japan Labour Health and Welfare Organization
Other
Japan
NO
大阪労災病院 / Osaka Rosai Hospital
2015 | Year | 04 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2015 | Year | 02 | Month | 26 | Day |
2015 | Year | 04 | Month | 01 | Day |
2015 | Year | 03 | Month | 29 | Day |
2016 | Year | 04 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019602